SZLSF (StageZero Life Sciences) Cyclically Adjusted PB Ratio: (As of Jul. 12, 2026)


SZLSF StageZero Life Sciences Ltd SZLSF
10 GF Score
Price $0.00
View Full Analysis

What is StageZero Life Sciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


StageZero Life Sciences  (OTCPK:SZLSF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


StageZero Life Sciences Cyclically Adjusted PB Ratio Related Terms


StageZero Life Sciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Cyclically Adjusted PB Ratio Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.54 0.00 0.00 0.00 0.00

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SZLSF vs IDTA, TTOO, NSTM: Cyclically Adjusted PB Ratio Comparison

For the Diagnostics & Research subindustry, StageZero Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Cyclically Adjusted PB Ratio falls into.


SZLSF
10GF Score
StageZero Life Sciences Ltd SZLSF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

StageZero Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, StageZero Life Sciences's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.09/127.2847*127.2847
=-0.090

Current CPI (Sep. 2024) = 127.2847.

StageZero Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201409 0.652 99.394 0.835
201412 0.338 98.367 0.437
201503 0.353 99.789 0.450
201506 0.186 100.500 0.236
201509 -0.005 100.421 -0.006
201512 -0.253 99.947 -0.322
201603 -0.538 101.054 -0.678
201606 -0.635 102.002 -0.792
201609 -0.687 101.765 -0.859
201612 -0.463 101.449 -0.581
201703 -0.468 102.634 -0.580
201706 -0.359 103.029 -0.444
201709 -0.291 103.345 -0.358
201712 -0.253 103.345 -0.312
201803 -0.194 105.004 -0.235
201806 -0.257 105.557 -0.310
201809 -0.288 105.636 -0.347
201812 -0.287 105.399 -0.347
201903 -0.451 106.979 -0.537
201906 -0.372 107.690 -0.440
201909 -0.164 107.611 -0.194
201912 -0.132 107.769 -0.156
202003 -0.166 107.927 -0.196
202006 -0.080 108.401 -0.094
202009 -0.165 108.164 -0.194
202012 -0.020 108.559 -0.023
202103 -0.069 110.298 -0.080
202106 0.008 111.720 0.009
202109 0.045 112.905 0.051
202112 0.030 113.774 0.034
202203 0.028 117.646 0.030
202206 0.014 120.806 0.015
202209 0.014 120.648 0.015
202212 -0.071 120.964 -0.075
202303 -0.084 122.702 -0.087
202306 -0.069 124.203 -0.071
202309 -0.074 125.230 -0.075
202403 -0.083 126.258 -0.084
202406 -0.087 127.522 -0.087
202409 -0.090 127.285 -0.090

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for SZLSF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price